Sotatercept as a Therapeutic Option for Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension With Features of PVOD/PCH
Yujin Nishioka, Keita Imanishi, Erika Matsuda, Wataru Nakamura, Ryosuke Shirayanagi, Hiroto Ojiro, Akira Katagiri · 2026
Read Sotatercept as a Therapeutic Option for Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension With Features of PVOD/PCH by Yujin Nishioka, Keita Imanishi, Erika Matsuda, Wataru Nakamura, Ryosuke Shirayanagi, Hiroto Ojiro, Akira Katagiri (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13291711.txt.
Description
A new drug eased hard lung hypertension in a tough case. Yujin Nishioka and colleagues report this 2026 case from Japan. Their patient was a 53-year-old woman with systemic sclerosis. Her lung arteries narrowed while vein disease lurked too.
Three oral drugs failed to hold her disease back. Lung pressure climbed steeply despite that care. Standard infused drugs risked flooding her lungs. Sotatercept was chosen to dodge that risk. Her walking distance and heart strain marks improved. Lung pressure eased down as well. Pauses for high hemoglobin did not undo gains. No lung flooding occurred during care.
Catalog record
| CREATOR | Yujin Nishioka, Keita Imanishi, Erika Matsuda, Wataru Nakamura, Ryosuke Shirayanagi, Hiroto Ojiro, Akira Katagiri |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 10748 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |